Therapeutic Asset Ratings
1,553 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Fludarabine
CAR-T
Zhimin Zhai
Early P1
C
(39)
Fludarabine
CAR-T Cell Therapy
TCRCure Biopharma Ltd.
Early P1
C
(39)
Fludarabine
Effects of Immunotherapy
Shanghai Juncell Therapeutics
Early P1
C
(39)
Fludarabine
Epithelial Tumors, Malignant
Vall d'Hebron Institute of Oncology
Early P1
C
(39)
Fludarabine
Idiopathic Inflammatory Myopathy
Tongji Hospital
Early P1
C
(39)
Fludarabine
IgAN - IgA Nephropathy
The Children's Hospital of Zhejiang University School of Medicine
Early P1
C
(39)
Fludarabine
Multi-Drug Resistant Nephrotic Syndrome
The Children's Hospital of Zhejiang University School of Medicine
Early P1
C
(39)
Fludarabine
Multiple Cancer
Zhejiang University
Early P1
C
(39)
Fludarabine
POEMS Syndrome
Tongji Hospital
Early P1
C
(39)
Fludarabine
Recurrent or Metastatic Solid Tumors With Positive ALPP
Haifeng Qin
Early P1
C
(39)
Fludarabine
SLE - Systemic Lupus Erythematosus
The Children's Hospital of Zhejiang University School of Medicine
Early P1
C
(39)
Fludarabine
SSc-Systemic Sclerosis
The Children's Hospital of Zhejiang University School of Medicine
Early P1
C
(39)
Fludarabine
Treatment Side Effects
Shanghai Juncell Therapeutics
Early P1
C
(39)
Fludarabine
Tumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Early P1
C
(39)
FLUDEOXYGLUCOSE
PET/CT Imaging
Peking Union Medical College Hospital
Early P1
C
(39)
FLUDEOXYGLUCOSE
Positron Emission Tomography
University of California, Davis
Early P1
C
(39)
FLUOROURACILUM
Mucositis
Tanta University
Early P1
C
(39)
Fruquintinib
Advanced Malignant Solid Tumor of Digestive System
Peking University
Early P1
C
(39)
FULVESTRANT
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer Institute
Early P1
C
(39)
FULVESTRANT
Sarcoma
OHSU Knight Cancer Institute
Early P1
C
(39)
FULVESTRANT
Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Early P1
C
(39)
[Ga-68]MTP220
Malignant Pancreatic Neoplasm
Qiubai Li
Early P1
C
(39)
gc203 til
Effects of Immunotherapy
Shanghai Juncell Therapeutics
Early P1
C
(39)
gc203 til
Pancreatic Ductal Adenocarcinoma
Shanghai Juncell Therapeutics
Early P1
C
(39)
gc203 til
Iatrogenic Disease
Shanghai Juncell Therapeutics
Early P1
C
(39)
Showing 476 to 500 of 1,553 assets
Previous
Page 20 of 63
Next
